Need a quote from a Motley Fool analyst? Over the past decade, Recursion Pharmaceuticals, Inc. has built something truly ...

Delivered first clinical validation of the Recursion full stack AI Operating System in FAP, demonstrating translation from AI ...

Delivered first clinical validation of the Recursion full stack AI Operating System in FAP, demonstrating translation from AI ...

American Airlines quietly ended the ability for customers traveling on basic economy tickets to earn miles and status. Basic economy tickets are airlines' most restrictive and already do not allow for ...

On CNBC's “Mad Money Lightning Round,” on Thursday, Jim Cramer said Recursion Pharmaceuticals (NASDAQ: RXRX) has been “horrendous” and he does not like to recommend horrendous stocks. On the earnings ...

AI-leveraged drug development has become an $18 billion industry, but companies in the sector are experiencing some hardships. Beyond efforts to convenience investors their drugs are safe and ...

Recursion now believes it has sufficient cash runway to reach the end of 2027, with partnerships potentially meaningfully extending this. For example, partnerships have provided Recursion with ...

In this week’s edition of InnovationRx, we look at a new biotech fund spearheaded by Recursion, a shift in bird flu strategy from the Trump Administration, a new vaccine approval from the FDA, ...